Inanovate has combined expertise from nano-scale physics, bio-engineering, bio-chemistry and biotechnology to create a unique mutliplexed protein screening technology called Longitudinal Assay Screening (LAS), designed to help advance the development and implementation of next generation therapeutics and clinical diagnostics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/04/19 | $3,100,000 | Series C |
Sanford Frontiers South Dakota Equity Partners  T. Denny Sanford | undisclosed |
